{
    "root": "f6dce609-c7d7-48a3-83bb-32ecf00f973f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Droxidopa"
    },
    "value": "20250225",
    "ingredients": [
        {
            "name": "DROXIDOPA",
            "code": "J7A92W69L7"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "droxidopa capsules indicated treatment orthostatic dizziness , lightheadedness , “ feeling black ” adult patients symptomatic neurogenic orthostatic hypotension ( noh ) caused primary autonomic failure ( parkinson 's disease [ pd ] , multiple system atrophy , pure autonomic failure ) , dopamine beta-hydroxylase deficiency , non-diabetic autonomic neuropathy . effectiveness beyond 2 weeks treatment established . continued effectiveness droxidopa capsules assessed periodically .",
    "contraindications": "starting dose 100 mg three times day ( 2.1 ) titrate 100 mg three times daily , maximum dose 600 mg three times daily ( 2.1 ) take consistently without food ( 2.1 ) reduce potential supine hypertension , elevate head bed give last dose least 3 hours prior bedtime ( 2.1 ) take droxidopa capsule whole ( 2.1 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "droxidopa capsules contraindicated patients history hypersensitivity ingredients [ ( 5.4 ) ] .",
    "indications_original": "Droxidopa capsules is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of droxidopa capsules should be assessed periodically.",
    "contraindications_original": "Starting dose is 100 mg three times during the day ( 2.1 ) Titrate by 100 mg three times daily, up to a maximum dose of 600 mg three times daily ( 2.1 ) Take consistently with or without food ( 2.1 ) To reduce the potential for supine hypertension, elevate the head of the bed and give the last dose at least 3 hours prior to bedtime ( 2.1 ) Take Droxidopa capsule whole ( 2.1 )",
    "adverseReactions_original": "Droxidopa capsules is contraindicated in patients who have a history of hypersensitivity to the drug or its ingredients [see Warnings and Precautions (5.4)]."
}